The global severity of chronic graft-versus-host disease, determined by national institutes of health consensus criteria, is associated with overall survival and non-relapse mortality

Haematologica

Volumn 96, Issue 11, 2011, Pages 1678-1684

  Pidala, Joseph ^a   Kim, Jongphil ^a   Anasetti, Claudio ^a   Nishihori, Taiga ^a   Betts, Brian ^a   Field, Teresa ^a   Perkins, Janelle ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Chronic graft versus host disease; NIH criteria; Non relapse mortality; Overall survival; Transplantation outcome

Indexed keywords

BUSULFAN; FLUDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH CONSENSUS CRITERIA; OVERALL SURVIVAL; PROGNOSIS; RELAPSE; THROMBOCYTE COUNT;

ACUTE DISEASE; ADULT; AGED; COHORT STUDIES; CONSENSUS DEVELOPMENT CONFERENCES, NIH AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 80355125818     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.049841     Document Type: Article

References (25)

1. Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008:134-41.
2. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, et al. Severity of chronic graftversus-host disease: association with treatment- related mortality and relapse. Blood. 2002;100(2):406-14.
3. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(4):215-33.
4. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114(1):7-19.
5. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12): 945-56.
6. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-9.
7. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15 (6):825-8.
8. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals Of Statistics 1988;16: 1141-54.
9. Fine J. A proportional hazards model for the subdistribution of a competing risk. JASA. 1999;94:496-509.
10. Cho BS, Min CK, Eom KS, Kim YJ, Kim HJ, Lee S, et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia. 2009;23(1):78-84.
11. Perez-Simon JA, Encinas C, Silva F, Arcos MJ, Diez-Campelo M, Sanchez-Guijo FM, et al. Prognostic factors of chronic graft-versushost disease following allogeneic peripheral blood stem cell transplantation: the National Institutes Health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant. 2008;14(10):1163-71.
12. Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, et al. Duration of immunosuppressive treatment for chronic graft-versushost disease. Blood. 2004;104 (12):3501-6.
13. Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem HP, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009;114(3):702-8.
14. Wingard JR, Piantadosi S, Vogelsang GB, Farmer ER, Jabs DA, Levin LS, et al. Predictors of death from chronic graft-versushost disease after bone marrow transplantation. Blood. 1989;74(4):1428-35.
15. Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S, et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood. 2003;102(3):802-9.
16. Pavletic SZ, Smith LM, Bishop MR, Lynch JC, Tarantolo SR, Vose JM, et al. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol. 2005;78(4):265-74.
17. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980; 69(2):204-17.
18. Arora M, Burns LJ, Davies SM, Macmillan ML, Defor TE, Miller WJ, et al. Chronic graftversus-host disease: a prospective cohort study. Biol Blood Marrow Transplant. 2003;9(1):38-45.
19. Arora M, Nagaraj S, Wagner JE, Barker JN, Brunstein CG, Burns LJ, et al. Chronic graftversus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood Marrow Transplant. 2007;13(10):1145-52.
20. Jagasia M, Giglia J, Chinratanalab W, Dixon S, Chen H, Frangoul H, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant. 2007;13(10):1207-15.
21. Arora M, Nagaraj S, Witte J, DeFor TE, MacMillan M, Burns LJ, et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant. 2009;43(2):149-53.
22. Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versushost disease. Biol Blood Marrow Transplant. 2002;8(8):444-52.
23. Herzberg PY, Heussner P, Mumm FH, Horak M, Hilgendorf I, von Harsdorf S, et al. Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(12): 1707-17.
24. Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108 (8):2867-73.
25. Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood;117(17):4651-7.